Sonnet BioTherapeutics Holdings Inc. is a clinical-stage biotech company developing innovative biologic drugs using its proprietary albumin binding technology to address unmet medical needs.

Sonnet BioTherapeutics Holdings Inc. has seen its stock price decline by over 15% to $3.49, but remains a point of interest for investors due to its innovative approach to cancer treatment development.

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotech company revolutionizing healthcare with its groundbreaking albumin binding technology, poised to make a lasting impact on the industry.

Sonnet BioTherapeutics Holdings Inc. is a clinical-stage biotech company pioneering fully human albumin binding technology to develop targeted biologic drugs, potentially transforming treatment paradigms and redefining possibilities within healthcare.